Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) has successfully completed an underwritten public offering, raising approximately $97.7 million. The offering included 7,344,543 shares of common stock at $11.00 each and 23,126 shares of Series B Preferred stock priced at $733.37 each, convertible into about 1,541,810 shares of common stock. Proceeds will fund the advancement of its VRDN-001 and VRDN-002 programs and preclinical developments of VRDN-004 and VRDN-005, alongside general corporate purposes. Jefferies, SVB Leerink, and Evercore ISI were the lead managers for this offering.
Viridian Therapeutics (NASDAQ: VRDN) has priced an underwritten public offering for gross proceeds of approximately $85.0 million. The offering consists of 6,185,454 shares of common stock priced at $11.00 per share and 23,126 shares of series B preferred stock at $733.37 per share, convertible into approximately 1,541,810 shares of common stock. Proceeds will be used for the development of VRDN-001, VRDN-002, VRDN-004, and VRDN-005 programs, as well as general corporate purposes. The offering is expected to close on or about September 23, 2021.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a public offering of its common stock and Series B preferred stock. The offering includes a 30-day option for underwriters to purchase additional common shares. Proceeds will support the advancement of VRDN-001 and VRDN-002 programs, along with preclinical development of VRDN-004 and VRDN-005, in addition to general working capital. Jefferies, SVB Leerink, and Evercore ISI are managing the offering. Regulatory filings are underway, emphasizing that this does not constitute an offer to sell these securities.
Viridian Therapeutics (VRDN) announced a successful pre-IND meeting with the FDA for its lead candidate, VRDN-001, targeting Thyroid Eye Disease (TED). The IND filing is expected in Q4 2021, with Phase 1/2 clinical data anticipated in Q2 2022. The company reported $109 million in cash and equivalents as of June 30, 2021, allowing operations to continue into 2024. R&D expenses rose to $12.6 million due to advancements in lead programs, while net loss increased to $18 million.
Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., and Barrett Katz, M.D., will participate in a panel presentation at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. The panel, titled TED Talk – State of Play in Thyroid Eye Disease, is scheduled for 1:45 p.m. ET. Webcast details can be found on the company’s website, and a replay will be available for 90 days after the live event. Viridian's lead program, VRDN-001, targets thyroid eye disease, an autoimmune condition affecting vision and causing significant patient discomfort.
Viridian Therapeutics (Nasdaq: VRDN) has appointed Kristian Humer as the new Chief Financial Officer and Chief Business Officer. Humer, with over 20 years of finance experience, will enhance the leadership team as they advance their investigational therapies pipeline, particularly focusing on Thyroid Eye Disease. An inducement grant of 360,000 shares will be awarded to Humer, vesting over four years. This strategic appointment aims to strengthen the company’s growth trajectory and address significant unmet medical needs in serious diseases.
Viridian Therapeutics (Nasdaq: VRDN) announced the appointment of Jennifer Moses, CPA, to its Board of Directors and as Chair of the Audit Committee. This strategic move aims to leverage her extensive financial and biotechnological expertise to support the company's clinical development initiatives for VRDN-001 and VRDN-002. CEO Jonathan Violin highlighted the importance of her leadership in enhancing financial oversight and advancing the company's commitment to providing new treatment options for patients suffering from Thyroid Eye Disease.
Viridian Therapeutics (Nasdaq: VRDN) announced an option grant to purchase 180,000 shares of common stock as an inducement for a new employee. This Inducement Grant, approved by a majority of the independent directors, is outside the company’s equity incentive plan but adheres to its terms. The exercise price is set at $17.20, matching the stock's closing price on July 6, 2021. The shares will vest over four years, with 25% vesting on the first anniversary, followed by monthly vesting. Viridian focuses on developing treatments for serious diseases, including TED, using monoclonal antibodies.
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on innovative treatments for serious diseases, announced that its CEO, Jonathan Violin, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 9:00 a.m. ET. The event will be held virtually, and the presentation can be accessed through Viridian's website. The company is known for its monoclonal antibody program, VRDN-001, targeting Thyroid Eye Disease (TED), which causes significant discomfort and potential blindness.
Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., its CEO, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 2:30 p.m. ET. This virtual event will focus on the company’s advancements in biopharmaceuticals for serious diseases. Interested parties can access the webcast on Viridian's website, with a replay available for 90 days post-event. Viridian is developing VRDN-001, targeting the debilitating autoimmune disease TED, which can lead to vision impairment.